All In Biotech

Drug Trial Radar · NCT06445959

Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Aug 29, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2029

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rigel Pharmaceuticals,Inc.
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.

Conditions

  • Mutant IDH1 Inhibitor Olutasidenib

Interventions

  • OlutasidenibDrug

    Given by PO

  • VenetoclaxDrug

    Given by PO

  • DecitabineDrug

    Given by IV

  • Decitabine/cedazuridineDrug

    Given by PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse events (AEs)Time frame: Through study completion; an average of 1 year.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida · Recruiting

  • The University of Kansas Medical Center

    Westwood, Kansas · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Roswell Park

    Buffalo, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.